Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q3

4483.TEDINET S100Q8QG
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥19.5bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥7.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Revenue¥21.8bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥15.7bn2021-04-01 → 2021-12-31Cons.Revenue IFRS
Revenue¥6.1bn2021-10-01 → 2021-12-31dCons.Revenue IFRS
Operating income¥4.0bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥1.8bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥3.4bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥1.7bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥4.0bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥1.8bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.4bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥1.7bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥2.7bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥2.3bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.1bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥2.7bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥1.2bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥2.3bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥1.1bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥95.1bnat 2022-12-31Cons.Assets IFRS
Total assets¥62.1bnat 2022-03-31Cons.Assets IFRS
Total assets¥60.4bnat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥32.3bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥30.9bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥62.9bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥30.1bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥28.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥62.9bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.2bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥30.1bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥21.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.5bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.9bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥2.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥3.8bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.9bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥21.8bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥8.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥5.3bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥27.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥2.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥2.1bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥44.982022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.282022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥57.742021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥40.462021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥20.162021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥42.662022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥18.452022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥54.162021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥38.142021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥18.992021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio66.1%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio49.9%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 72
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥189m
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥62m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥189m
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥62m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥417m
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥227m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-12-31¥2.8bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-10-01 → 2022-12-31¥944m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-12-31¥2.7bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-10-01 → 2022-12-31¥901m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥127m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥43m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-12-31¥310m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-10-01 → 2022-12-31¥118m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-12-31¥13.1bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2022-10-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-12-31¥13.1bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-10-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥62m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥19m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-12-31¥4.0bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-10-01 → 2022-12-31¥2.0bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2022-10-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2022-10-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2022-10-01 → 2022-12-31¥492m
—segment totalrevenue2022-04-01 → 2022-12-31¥19.7bn
—segment totalrevenue2022-10-01 → 2022-12-31¥7.5bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥19.5bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥7.5bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥189m
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥62m
—segment totalsegment profit2022-04-01 → 2022-12-31¥5.7bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥2.6bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥143m
Reconciling Itemsreconcilingrevenue2021-10-01 → 2021-12-31−¥54m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥143m
Reconciling Itemsreconcilingrevenue intersegment2021-10-01 → 2021-12-31−¥54m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥242m
Reconciling Itemsreconcilingsegment profit2021-10-01 → 2021-12-31−¥85m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2021-04-01 → 2021-12-31¥2.6bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2021-10-01 → 2021-12-31¥907m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2021-04-01 → 2021-12-31¥2.5bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2021-10-01 → 2021-12-31¥873m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥90m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥34m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2021-04-01 → 2021-12-31¥209m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2021-10-01 → 2021-12-31¥46m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2021-04-01 → 2021-12-31¥9.9bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2021-10-01 → 2021-12-31¥4.1bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2021-04-01 → 2021-12-31¥9.8bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2021-10-01 → 2021-12-31¥4.0bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥52m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥20m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2021-04-01 → 2021-12-31¥3.4bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2021-10-01 → 2021-12-31¥1.7bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2021-04-01 → 2021-12-31¥3.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2021-10-01 → 2021-12-31¥1.2bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2021-04-01 → 2021-12-31¥3.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2021-10-01 → 2021-12-31¥1.2bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2021-04-01 → 2021-12-31¥1.2bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2021-10-01 → 2021-12-31¥470m
—segment totalrevenue2021-04-01 → 2021-12-31¥15.8bn
—segment totalrevenue2021-10-01 → 2021-12-31¥6.2bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥15.7bn
—segment totalrevenue external2021-10-01 → 2021-12-31¥6.1bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥143m
—segment totalrevenue intersegment2021-10-01 → 2021-12-31¥54m
—segment totalsegment profit2021-04-01 → 2021-12-31¥4.8bn
—segment totalsegment profit2021-10-01 → 2021-12-31¥2.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 842
ItemContextValueUnit
Revenue IFRSPrior1QuarterDuration_ReportableSegmentsMember6183000000JPY
Revenue IFRSPrior1QuarterDuration_ReconcilingItemsMember-54000000JPY
Revenue IFRSPrior1QuarterDuration6128000000JPY
Segment profit loss IFRSPrior1QuarterDuration_jpcrp040300-q3r_E35308-000HealthcareBigDataReportableSegmentMember1677000000JPY
Segment profit loss IFRSPrior1QuarterDuration_jpcrp040300-q3r_E35308-000TeleMedicineReportableSegmentMember470000000JPY
Segment profit loss IFRSPrior1QuarterDuration_jpcrp040300-q3r_E35308-000DispensingPharmacySupportReportableSegmentMember46000000JPY
Segment profit loss IFRSPrior1QuarterDuration_ReportableSegmentsMember2193000000JPY
Segment profit loss IFRSPrior1QuarterDuration_ReconcilingItemsMember-85000000JPY
Segment profit loss IFRSPrior1QuarterDuration2107000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E35308-000HealthcareBigDataReportableSegmentMember5221000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E35308-000TeleMedicineReportableSegmentMember1359000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E35308-000DispensingPharmacySupportReportableSegmentMember901000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_ReportableSegmentsMember7482000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentQuarterDuration7482000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E35308-000HealthcareBigDataReportableSegmentMember19000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E35308-000TeleMedicineReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E35308-000DispensingPharmacySupportReportableSegmentMember43000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_ReportableSegmentsMember62000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_ReconcilingItemsMember-62000000JPY
Intersegment revenue IFRSCurrentQuarterDuration－JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E35308-000HealthcareBigDataReportableSegmentMember5241000000JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E35308-000TeleMedicineReportableSegmentMember1359000000JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E35308-000DispensingPharmacySupportReportableSegmentMember944000000JPY
Revenue IFRSCurrentQuarterDuration_ReportableSegmentsMember7545000000JPY
Revenue IFRSCurrentQuarterDuration_ReconcilingItemsMember-62000000JPY
Revenue IFRSCurrentQuarterDuration7482000000JPY
Segment profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E35308-000HealthcareBigDataReportableSegmentMember1993000000JPY
Segment profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E35308-000TeleMedicineReportableSegmentMember492000000JPY
Segment profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E35308-000DispensingPharmacySupportReportableSegmentMember118000000JPY
Segment profit loss IFRSCurrentQuarterDuration_ReportableSegmentsMember2603000000JPY
Segment profit loss IFRSCurrentQuarterDuration_ReconcilingItemsMember-227000000JPY
Segment profit loss IFRSCurrentQuarterDuration2376000000JPY
Segment profit loss IFRSPrior1QuarterDuration2107000000JPY
Segment profit loss IFRSCurrentQuarterDuration2376000000JPY
Depreciation and amortization operating expenses IFRSPrior1QuarterDuration440000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration551000000JPY
Other income IFRSPrior1QuarterDuration14000000JPY
Other income IFRSCurrentQuarterDuration0JPY
Other expenses IFRSPrior1QuarterDuration9000000JPY
Other expenses IFRSCurrentQuarterDuration3000000JPY
Operating profit loss IFRSPrior1QuarterDuration1672000000JPY
Operating profit loss IFRSCurrentQuarterDuration1821000000JPY
Finance income IFRSPrior1QuarterDuration22000000JPY
Finance income IFRSCurrentQuarterDuration0JPY
Finance costs IFRSPrior1QuarterDuration14000000JPY
Finance costs IFRSCurrentQuarterDuration47000000JPY
Profit loss before tax IFRSPrior1QuarterDuration1681000000JPY
Profit loss before tax IFRSCurrentQuarterDuration1773000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass